Related Experiment Video
Updated: Apr 5, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?
1Radiation Therapy Department, Saint Savvas anticancer institute of Athens, Alexandra's Avenue 171, 115 22 Athens, Greece. gkoyokoyrakis@yahoo.gr.
Abstract:
Recently, the improvement of innovative medications named focused treatments represents the consequence of a superior knowledge of the procedures implicated in the modification of physiological tissues in tumor. Focused treatment is known as the therapy which uses specific substances that affect selective mechanisms implicated in tumorigenesis and tumor development. Angiogenesis is important for tumor development and distant metastatic disease and represents a significant aim for modern biological substances. Bevacizumab belongs to humanized recombinant antibody family which obviates vascular endothelial growth factor (VEGF) receptor fastening, and suspending genesis of new vessels and tumor development. Bevacizumab represents the primary antiangiogenic treatment authorized for usage in tumor and has FDA authorization to treat the recurrent glioblastoma multiform since 2009. Bevacizumab's efficiency for treating malignant brain gliomas along with correlated patent appliances related to this agent is discussed below.
Insights
Focused treatments, like bevacizumab, target tumor growth mechanisms. This therapy inhibits angiogenesis, crucial for tumor development and metastasis, offering a new approach for brain gliomas.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted therapies represent advancements in cancer treatment.
- Understanding tumor biology, including angiogenesis, is key to developing new drugs.
- Bevacizumab is a targeted therapy impacting tumor vascularization.
Purpose of the Study:
- To discuss the efficacy of bevacizumab in treating malignant brain gliomas.
- To explore patent applications related to bevacizumab.
- To highlight bevacizumab as a primary antiangiogenic treatment.
Main Methods:
- Review of scientific literature on targeted therapies and angiogenesis.
- Analysis of bevacizumab's mechanism of action.
- Examination of FDA approvals and patent landscape for bevacizumab.
Main Results:
- Bevacizumab inhibits vascular endothelial growth factor (VEGF) receptor binding.
- This inhibition prevents new blood vessel formation (angiogenesis).
- Bevacizumab is FDA-approved for recurrent glioblastoma multiforme.
Conclusions:
- Bevacizumab is an effective antiangiogenic agent for brain gliomas.
- Targeted therapies like bevacizumab represent a significant step in cancer treatment.
- Further research and patent exploration are ongoing for bevacizumab and similar agents.
